Rheumatoid arthritis disease measurement: A new old idea

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL. 6, 2012, Pages

  Hobbs, Kathryn F ^a,b   Cohen, Marc D ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Denver Arthritis Clinic PC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

ACR20 50 70 scores; CDAI; DAS28; HAQ; Measures of disease activity; RAPID; Rheumatoid arthritis; SDAI

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEPTIN; METHOTREXATE; PREDNISONE; RESISTIN; RITUXIMAB; SERUM AMYLOID A; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL TRIAL (TOPIC); DECISION MAKING; DISEASE ACTIVITY; DRUG DEVELOPMENT; DRUG MEGADOSE; ECHOGRAPHY; HUMAN; LICENSING; MEASUREMENT; MEDICAL PRACTICE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; ENDPOINT DETERMINATION; HEALTH STATUS INDICATORS; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870896036     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes282     Document Type: Article

References (57)

1. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S, Eliasson B. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30: 496-502.
2. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004;94:4F-8F.
3. Egan BM, Lackland DT, Cutler NE. Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. Arch Intern Med 2003;163:681-7.
4. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27: 864-72.
5. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29: 706-14.
6. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108-11.
7. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
8. van Leeuwen MA, van der Heijde DM, van Rijswijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
9. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
10. Welsing PM, Landewe RB, van Riel PL et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
11. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8.
12. Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
13. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
14. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
15. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729-40.
16. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
17. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
18. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
19. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44, vii.
20. Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum 2008;58:2622-31.
21. Aletaha D, Landewe R, Karonitsch T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008;59:1371-7.
22. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
23. van der Heide A, Jacobs JW, Bijlsma JW et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
24. van der Heijde D, Klareskog L, Boers M et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005;64: 1582-7.
25. Makinen H, Kautiainen H, Hannonen P et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34: 316-21.
26. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
27. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
28. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
29. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
30. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
31. Verstappen SM, Jacobs JW, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
32. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
33. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
34. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66(Suppl. 3):iii56-60.
35. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
36. Cush JJ. Disease outcome measures used to monitor disease activity and progression in patients with rheumatoid arthritis. Presented at 2005 ACR Annual Scientific Meeting; San Diego, CA, 12-17 November 2005. Abstract 1854.
37. Sesin CA, Bingham 3rd CO. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005;35:185-96.
38. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006;43(Suppl. 43):S22-8.
39. Yazici Y. Monitoring response to treatment in rheumatoid arthritis-which tool is best suited for routine 'real world' care? Bull NYU Hosp Jt Dis 2007;65(Suppl. 1):S25-8.
40. Gulfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis 2005;64:1186-9.
41. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology 2000;39: 321-7.
42. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(5 Suppl. 39):S100-8.
43. Bakker MF, Shen Y, Bijlsma WJ et al. Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA) [abstract]. Arthritis Rheum 2010; 62(Suppl. 10):1753.
44. Qureshi F, Manning W, Eastman S, Hu W, Centola M, Turner M. Pre analytical effects of serum collection and handling in quantitative immunoassays for rheumatoid arthritis [abstract] Arthritis Rheum 2010;62(Suppl. 10): 1606.
45. Curtis JR, Haney D, van der Helm AHM et al. Validation of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA) in a multi-cohort study [abstract]. Arthritis Rheum 2010;62(Suppl. 10):1782.
46. Ma MH, Ramanujan S, Haney DJ et al. Biomarker signatures in rheumatoid arthritis patients with low disease activity: the REMIRA study. Ann Rheum Dis 2011; 70(Suppl. 3):1444-53.
47. Weinblatt M, Shadick NA, Manning W et al. Use of a mulit-bimarker score for rheumatoid arthritis disease activity (VECTRATM DA) to assess response to therapy. Ann Rheum Dis 2011;70(Suppl. 3):290.
48. Allaart CF, Dirven L, Hirata S et al. A multi-biomarker disease activity (Vectra DA) algorithm score for rheumatoid arthritis predicts radiographic progression in the BeSt study [abstract]. Arthritis Rheum 2011;63(Suppl. 10):1613.
49. van der Helm-van Mil AH, Kneve LR, Manning W et al. Development of a multi-biomarker algorithm to predict RA structural damage in the Leiden early arthritis cohort. Ann Rheum Dis 2011;70(Suppl. 3):350.
50. Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
51. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
52. Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
53. Tak PP, Rigby WF, Rubbert-Roth A et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
54. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, doubleblind, parallel treatment trial. Lancet 2008;372:375-82.
55. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
56. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70: 315-9.
57. Weisman MH. Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum 2005;52: 3326-32.